Welcome to BioSeeker Group!

A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Additional Information

Published Date May 18, 2011
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 954
PDF Fact Sheet View Fact Sheet for the report A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

Regular Price: $1,950.00

Special Price: $975.00

Quick Overview

This report comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 152 companies, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and five subindications of lymphoma.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market.

    To find out more about A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This report comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 152 companies, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and five subindications of lymphoma. BioSeeker has applied its unique drug assessment methodology to stratify the lymphoma pipeline and discern the level of competition in fine detail.

Major Findings from this report:

* The identified competitive landscape of lymphoma drugs is split between the 49% which have unique drug target strategies and the other part which have head-to-head target competing lymphoma drugs in 36 different clusters. The latter has a competing ratio which is almost two and a half times higher than the comparable average of the lymphoma drugs in general. Contributing to this fact is heavily utilized drug target strategies like: MS4A1, TOP2A, ALK and CD19.

* Eight out of ten drug target strategies in Phase III development are new to lymphoma drugs and at the same time the greatest numbers of new target strategies are found in Phase I (33%) and Phase II development (27%).

* Small molecules, antibodies and proteins are the dominating compound strategies of lymphoma drugs, which represent 90% of the entire pipeline. Cell- and gene therapy based lymphoma drugs have the lowest representation in the defined target strategy portfolio compared to that of other compound strategies of lymphoma drugs.

* The highest number of described drug target strategies of lymphoma drugs belongs to Bristol-Myers Squibb (9), Hoffmann-La Roche (8), GlaxoSmithKline (8) and Pfizer (8).

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any lymphoma drug to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary 3
2 About Cancer Highlights™ 5
2.1 Cancer Focus Areas 5
2.2 Subscribe Today and Start Saving 6
2.2.1 Type of License 6
2.3 Additional Information 6
2.4 BioSeeker Group’s Oncology Team 6
3 Methodology 7
3.1 Cancer Highlights’™ Five Pillar Drug Assessment 7
4 Table of Contents 9
4.1 List of Figures 19
4.2 List of Tables 19
5 Introduction 26
5.1 The Scope of this Report 26
5.2 Definitions 29
5.3 Abbreviations 29
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment 30
6.1 Drug Repositioning in Oncology 30
6.2 Introduction to Targets of Lymphoma Drugs 31
6.2.1 Acid Phosphatase Activity Targets 38
6.2.2 Auxiliary Transport Protein Activity Targets 39
6.2.3 Carboxy-lyase Activity Targets 40
6.2.4 Caspase Activator Activity Targets 41
6.2.5 Catalytic Activity Targets 42
6.2.6 Cell Adhesion Molecule Activity Targets 50
6.2.7 Chaperone Activity Targets 53
6.2.8 Chemokine Activity Targets 56
6.2.9 Cysteine-type Peptidase Activity Targets 58
6.2.10 Cytokine Activity Targets 61
6.2.11 Deaminase Activity Targets 68
6.2.12 DNA Binding Targets 69
6.2.13 DNA Repair Protein Targets 71
6.2.14 DNA Topoisomerase Activity Targets 72
6.2.15 DNA-directed DNA Polymerase Activity Targets 76
6.2.16 DNA-methyltransferase Activity Targets 82
6.2.17 G-protein Coupled Receptor Activity Targets 83
6.2.18 Glutathione Transferase Activity Targets 86
6.2.19 Growth Factor Activity Targets 88
6.2.20 GTPase Activator Activity Targets 91
6.2.21 Hormone Activity Targets 92
6.2.22 Hydrolase Activity Targets 93
6.2.23 Kinase Activity Targets 96
6.2.24 Kinase Binding Targets 107
6.2.25 Kinase Regulator Activity Targets 110
6.2.26 Ligand-dependent Nuclear Receptor Activity Targets 111
6.2.27 Ligase Activity Targets 115
6.2.28 Lipid Kinase Activity Targets 122
6.2.29 Lipid Phosphatase Activity Targets 130
6.2.30 MHC Class I Receptor Activity Targets 131
6.2.31 Molecular Function Unknown Targets 132
6.2.32 Motor Activity Targets 136
6.2.33 Oxidoreductase Activity Targets 138
6.2.34 Phosphorylase Activity Targets 143
6.2.35 Protein Binding Targets 145
6.2.36 Protein Serine/Threonine Kinase Activity Targets 149
6.2.37 Protein Threonine/Tyrosine Kinase Activity Targets 180
6.2.38 Protein-tyrosine Kinase Activity Targets 185
6.2.39 Receptor Activity Targets 196
6.2.40 Receptor Binding Targets 220
6.2.41 Receptor Signaling Complex Scaffold Activity Targets 226
6.2.42 RNA Binding Targets 232
6.2.43 Serine-type Peptidase Activity Targets 233
6.2.44 Structural Constituent of Cytoskeleton Targets 234
6.2.45 Superoxide Dismutase Activity Targets 235
6.2.46 T Cell Receptor Activity Targets 237
6.2.47 Transcription Factor Activity Targets 242
6.2.48 Transcription Regulator Activity Targets 256
6.2.49 Translation Regulator Activity Targets 267
6.2.50 Transmembrane Receptor Activity Targets 271
6.2.51 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 277
6.2.52 Transporter Activity Targets 302
6.2.53 Ubiquitin-specific Protease Activity Targets 309
6.2.54 Other Targets 312
6.3 The Cancer Genome Project and Targets of Lymphoma Drugs 315
6.3.1 Targets of Lymphoma Drugs Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 315
6.4 Structure-based Drug Design in Lymphoma Therapeutics is Stimulated by Available Structure Data on Biological Targets 321
6.5 Target-Target Interactions among Identified Targets of Lymphoma Drugs 325
6.6 The Drug-Target Competitive Landscape 330
6.7 Protein Expression Levels of Identified Targets of Lymphoma Drugs 334
6.8 Pathway Assessment of Lymphoma Drugs 338
6.8.1 Tools for Analysis of Cancer Pathways 339
6.8.2 Pathway Assessment 340
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development 388
7.1 Pre-registration to Marketed: New and Unique Drug Target Strategies of Lymphoma Drugs 392
7.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Lymphoma Drugs 394
7.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Lymphoma Drugs 396
7.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Lymphoma Drugs 400
7.5 Preclinical Development: New and Unique Drug Target Strategies of Lymphoma Drugs 405
7.6 Drug Target Strategies of Suspended or Terminated Lymphoma Drugs 408
7.7 Target Strategy Development Profiles of Lymphoma Drugs 410
7.7.1 Marketed 414
7.7.2 Phase III 430
7.7.3 Phase II 439
7.7.4 Phase I 486
7.7.5 Preclinical 543
7.7.6 Suspended 565
7.7.7 Ceased 566
7.8 The Competition Through Close Mechanistic Approximation of Lymphoma Drugs 591
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy 597
8.1 Small Molecules 599
8.1.1 Background 599
8.1.2 Target Strategies of Small Molecule Drugs 600
8.2 Peptide & Protein Drugs 610
8.2.1 Background 610
8.2.2 Target Strategies of Peptide and Protein Drugs 611
8.3 Antibodies 616
8.3.1 Background 616
8.3.2 Target Strategies of Antibody Drugs 616
8.4 Nucleic Acid Therapies 622
8.4.1 Background 622
8.4.2 Target Strategies of Nucleic Acid Drugs 623
8.5 Cell & Gene Therapy 625
8.5.1 Background 625
8.5.2 Target Strategies of Cell and Gene Therapy Drugs 626
8.6 Drug Delivery and Nanotechnology 629
8.6.1 Background 629
8.6.2 Target Strategies of Reformulated Drugs 629
8.7 Compound Strategies based on Sub-Cellular Localization of Drug Targets 631
9 Selecting Subindication for Lymphoma Drugs 637
9.1 B-cell Lymphoma 638
9.2 Hodgkin’s Lymphoma 641
9.3 non-Hodgkin’s Lymphoma 644
9.4 T-cell Lymphoma 652
9.5 Lymphoma (general) 654
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator 658
10.1 Competitive Fall-Out Assessment 658
10.2 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 660
10.3 4SC 661
10.4 Abbott 662
10.5 Abiogen 664
10.6 Advaxis 666
10.7 AEgera 667
10.8 AEterna Zentaris 669
10.9 Affimed Therapeutics 670
10.10 Agenus 672
10.11 Aida Pharmaceuticals 674
10.12 Alfa Wassermann 675
10.13 Alfacell 676
10.14 Allos Therapeutics 678
10.15 Ambit Biosciences 680
10.16 Amgen 681
10.17 Apricus Biosciences 684
10.18 Ariad 686
10.19 Arno Therapeutics 688
10.20 Ascenta Therapeutics 689
10.21 Astellas 691
10.22 Astex Therapeutics 694
10.23 AstraZeneca 695
10.24 Attenuon 698
10.25 AVEO 699
10.26 Bayer 700
10.27 Benitec 701
10.28 Biocon 702
10.29 BioCryst Pharmaceuticals 703
10.30 Biogen Idec 704
10.31 Biolex 709
10.32 Boehringer Ingelheim 711
10.33 Borean Pharma 712
10.34 Bristol-Myers Squibb 714
10.35 BTG 721
10.36 Celera 724
10.37 Celgene 726
10.38 Cell Therapeutics 729
10.39 Celldex Therapeutics 731
10.40 Celltrion 733
10.41 Cephalon 735
10.42 Cornerstone Pharmaceuticals 739
10.43 CureTech 740
10.44 Curis 741
10.45 Cyclacel 742
10.46 Cylene Pharmaceuticals 743
10.47 CytImmune Sciences 745
10.48 Cytokinetics 746
10.49 Daiichi Sankyo 748
10.50 Dainippon Sumitomo Pharma 750
10.51 Dara Biosciences 752
10.52 Dendreon 753
10.53 Dr Reddy’s 754
10.54 Dynavax Technologies 756
10.55 Eisai 757
10.56 Eleos 759
10.57 Eli Lilly 760
10.58 Emergent BioSolutions 764
10.59 Enzon 767
10.60 EpiCept 768
10.61 Epizyme 769
10.62 Exelixis 770
10.63 Favrille 774
10.64 Forma Therapeutics 776
10.65 Gemin X Biotechnologies 777
10.66 Genencor 778
10.67 Genentech 779
10.68 Genmab 781
10.69 GenPat77 784
10.70 Genta 785
10.71 Genzyme 786
10.72 Gilead Sciences 788
10.73 GlaxoSmithKline 790
10.74 Hayashibara 796
10.75 Heber Biotec 797
10.76 HemaQuest 798
10.77 Hoffmann-La Roche 799
10.78 Human Genome Sciences 805
10.79 Hy BioPharma 807
10.80 IGF Oncology 808
10.81 ImmunoGen 809
10.82 Immunomedics 810
10.83 Inex 814
10.84 Innate Pharma 815
10.85 InNexus Biotechnology 817
10.86 Inovio 820
10.87 Intas Biopharmaceuticals 821
10.88 Intracel 822
10.89 Italfarmaco 824
10.90 Johnson & Johnson 825
10.91 Kinex 827
10.92 Kissei 828
10.93 Kyowa Hakko Kirin 830
10.94 Leo 833
10.95 LG Life Sciences 834
10.96 Ligand 836
10.97 Lorus Therapeutics 838
10.98 MacroGenics 840
10.99 Meda 841
10.100 MedImmune 843
10.101 Merck & Co 844
10.102 Merck KGaA 846
10.103 MethylGene 848
10.104 Micromet 850
10.105 Nektar Therapeutics 852
10.106 Nereus Pharmaceuticals 853
10.107 Nerviano Medical Sciences 854
10.108 NIH – The US National Institute of Health 855
10.109 Non-industrial Sources 856
10.110 Novartis 858
10.111 Noxxon 863
10.112 Nycomed Pharma 864
10.113 Onconova 866
10.114 Oncothyreon 868
10.115 Otsuka 869
10.116 Pfizer 870
10.117 Pharmacyclics 876
10.118 PharmaMar 878
10.119 Philogen 880
10.120 Piramal 881
10.121 Plexxikon 883
10.122 Portola Pharmaceuticals 884
10.123 ProNAi Therapeutics 886
10.124 Reata Pharmaceuticals 887
10.125 Regeneron 888
10.126 Reliance Life Sciences 889
10.127 Rigel 890
10.128 Sanofi-Aventis 892
10.129 Santaris Pharma 895
10.130 SBIO 897
10.131 Seattle Genetics 898
10.132 Selvita 901
10.133 Semafore Pharmaceuticals 902
10.134 Shire 903
10.135 SuperGen 904
10.136 SuppreMol 906
10.137 Synageva BioPharma 907
10.138 Takeda 909
10.139 Tapestry Pharmaceuticals 912
10.140 Tekmira Pharmaceuticals 914
10.141 Telik 915
10.142 TetraLogic Pharmaceuticals 916
10.143 Teva 917
10.144 Titan Pharmaceuticals 919
10.145 TopoTarget 920
10.146 Transgene 922
10.147 Trion Pharma 923
10.148 Vaccinex 925
10.149 VentiRx Pharmaceuticals 927
10.150 Vertex Pharmaceuticals 928
10.151 Vion Pharmaceuticals 929
10.152 XBiotech 931
10.153 Xencor 932
10.154 Yakult Honsha 934
10.155 Zenotech 935
10.156 Zenyaku Kogyo 937
11 Disclaimer 939
12 Drug Index 940
13 Company Index 948

4.1 List of Figures
Figure 1: Visualization of Target-Target Interactions among Targets of Lymphoma Drugs 329
Figure 2: The Drug-Target Competitive Landscape of Lymphoma Drugs - Large Clusters 331
Figure 3: The Drug-Target Competitive Landscape Lymphoma Drugs - Smaller Clusters 332
Figure 4: Head-to-Head Targeting Competitive Landscape of Lymphoma Drugs 333
Figure 5: Distribution of Compound Strategies among Lymphoma Drugs 631
Figure 6: Primary Sub-cellular Localization of Drug Targets 632

4.2 List of Tables
Table 1: Cancer Highlights’™ Five Pillar Drug Assessment 7
Table 2: Breakdown of the Included Lymphoma Drug Pipeline by Stage of Development 26
Table 3: Head to Head Target Competition among Lymphoma Drugs 26
Table 4: Overview of Drug Target Strategy Themes 31
Table 5: Terminally Ceased Targets of Lymphoma Drugs 32
Table 6: Official Gene Name to Target Profle 32
Table 7: Targets of Lymphoma Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 316
Table 8: Identity of Lymphoma Drug Targets with Available Biological Structures 321
Table 9: Number of Target-Target Interactions among Targets of Lymphoma Drugs 325
Table 10: Available Protein Expression Profiles of Lymphoma Drugs Targets 334
Table 11: Pathway Summary 340
Table 12: Drug Targets without any Identified Assigned Pathways 340
Table 13: Pathway Profiles According to BioCarta of Lymphoma Drug Targets 342
Table 14: Pathway Profiles According to KEGG of Lymphoma Drug Targets 361
Table 15: Pathway Profiles According to NetPath of Lymphoma Drug Targets 383
Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 388
Table 17: Top Competitive Target Strategies of Lymphoma Drugs 389
Table 18: New and Unique Target Strategies of Pre-registration and Marketed Lymphoma Drugs 392
Table 19: The Competition Through Close Mechanistic Approximation Between Lymphoma Drugs being Marketed or in Pre-registration 393
Table 20: New and Unique Target Strategies in Phase III Clinical Development of Lymphoma Drugs 394
Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Lymphoma Drugs 394
Table 22: New and Unique Target Strategies in Phase II Clinical Development of Lymphoma Drugs 396
Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Lymphoma Drugs 398
Table 24: New and Unique Target Strategies in Phase I Clinical Development of Lymphoma Drugs 400
Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Lymphoma Drugs 403
Table 26: New and Unique Target Strategies in Preclinical Development of Lymphoma Drugs 405
Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Lymphoma Drugs 406
Table 28: Target Strategies of Suspended and Terminated Lymphoma Drugs 408
Table 29: Connecting Target Strategy with Its Profile Identification Number 410
Table 30: The Competition Through Close Mechanistic Approximation Among Lymphoma Drugs 591
Table 31: Overview of Compound Strategy Competition Among Lymphoma Drugs 598
Table 32: Overview of the Competitive Landscape of Small Molecule Based Lymphoma Drugs 600
Table 33: Competitive Comparison of Target Strategies of Small Molecule Lymphoma Drugs 601
Table 34: Pursued Target Strategies of Small Molecule Drugs Based Lymphoma Drugs 604
Table 35: Overview of the Competitive Landscape of Peptide Based Lymphoma Drugs 611
Table 36: Pursued Target Strategies of Peptide Based Lymphoma Drugs 612
Table 37: Overview of the Competitive Landscape of Protein Based Lymphoma Drugs 613
Table 38: Competitive Comparison of Target Strategies of Protein Based Lymphoma Drugs 614
Table 39: Pursued Target Strategies of Protein Based Lymphoma Drugs 614
Table 40: Overview of the Competitive Landscape of Antibody Based Lymphoma Drugs 616
Table 41: Competitive Comparison of Target Strategies of Antibody Based Lymphoma Drugs 617
Table 42: Pursued Target Strategies of Antibody Based Lymphoma Drugs 619
Table 43: Overview of the Competitive Landscape of Nucleic Acid Based Lymphoma Drugs 623
Table 44: Competitive Comparison of Target Strategies of Nucleic Acid Based Lymphoma Drugs 624
Table 45: Pursued Target Strategies of Nucleic Acid Based Lymphoma Drugs 624
Table 46: Potential Forms of Cell Therapy 625
Table 47: Vectors in Gene Therapy 626
Table 48: Overview of the Competitive Landscape of Cell Therapy Based Lymphoma Drugs 626
Table 49: Pursued Target Strategies of Cell Therapy Based Lymphoma Drugs 626
Table 50: Overview of the Competitive Landscape of Gene Therapy Based Lymphoma Drugs 627
Table 51: Pursued Target Strategies of Gene Therapy Based Lymphoma Drugs 628
Table 52:Overview of the Competitive Landscape of Reformulated Lymphoma Drugs 629
Table 53: Competitive Comparison of Target Strategies of Reformulated Lymphoma Drugs 630
Table 54: Pursued Target Strategies of Reformulated Lymphoma Drugs 630
Table 55: Compound Strategies based on Sub-Cellular Localization of Lymphoma Drug Targets 632
Table 56 Competitive Summary by Subindication of Lymphoma Drugs 637
Table 57: Target Strategy Development Profiles of Drugs for the Treatment of B-cell Lymphoma Drugs 638
Table 58: The Competition through Close Mechanistic Approximation between B-cell Lymphoma Drugs 640
Table 59: Target Strategy Development Profiles of Drugs for the Treatment of Hodgkin’s Lymphoma 641
Table 60: The Competition through Close Mechanistic Approximation between Hodgkin’s Lymphoma Drugs 643
Table 61: Target Strategy Development Profiles of Drugs for the Treatment of non-Hodgkin’s Lymphoma 644
Table 62: The Competition through Close Mechanistic Approximation between non-Hodgkin’s Lymphoma Drugs 649
Table 63: Target Strategy Development Profiles of Drugs for the Treatment of T-cell Lymphoma 652
Table 64: The Competition through Close Mechanistic Approximation between T-cell Lymphoma Drugs 653
Table 65: Target Strategy Development Profiles of Drugs for the Treatment of Lymphoma (general) 654
Table 66: The Competition through Close Mechanistic Approximation between Lymphoma (general) Drugs 657
Table 67: Example of a Competitive Fall-Out Table (Targeting MS4A1) 659
Table 68: Summary Table of Corporate Changes in the Competitive Landscape of Lymphoma Drug Development 660
Table 69: 4SC’s Included Lymphoma Pipeline and Competitive Fall-Out 661
Table 70: Abbott’s Included Lymphoma Pipeline and Competitive Fall-Out 662
Table 71: Abiogen’s Included Lymphoma Pipeline and Competitive Fall-Out 664
Table 72: Advaxis’ Included Lymphoma Pipeline and Competitive Fall-Out 666
Table 73: AEgera’s Included Lymphoma Pipeline and Competitive Fall-Out 667
Table 74: AEterna Zentaris’ Included Lymphoma Pipeline and Competitive Fall-Out 669
Table 75: Affimed Therapeutics’ Included Lymphoma Pipeline and Competitive Fall-Out 670
Table 76: Agenus’ Included Lymphoma Pipeline and Competitive Fall-Out 672
Table 77: Aida Pharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out 674
Table 78: Alfa Wassermann’s Included Lymphoma Pipeline and Competitive Fall-Out 675
Table 79: Alfacell’s Included Lymphoma Pipeline and Competitive Fall-Out 676
Table 80: Allos Therapeutics’ Included Lymphoma Pipeline and Competitive Fall-Out 678
Table 81: Ambit Biosciences’ Included Lymphoma Pipeline and Competitive Fall-Out 680
Table 82: Amgen’s Included Lymphoma Pipeline and Competitive Fall-Out 681
Table 83: Apricus Biosciences’ Included Lymphoma Pipeline and Competitive Fall-Out 684
Table 84: Ariad’s Included Lymphoma Pipeline and Competitive Fall-Out 686
Table 85: Arno Therapeutics’ Included Lymphoma Pipeline and Competitive Fall-Out 688
Table 86: Ascenta Therapeutics’ Included Lymphoma Pipeline and Competitive Fall-Out 689
Table 87: Astellas’ Included Lymphoma Pipeline and Competitive Fall-Out 691
Table 88: Astex Therapeutics’ Included Lymphoma Pipeline and Competitive Fall-Out 694
Table 89: AstraZeneca’s Included Lymphoma Pipeline and Competitive Fall-Out 695
Table 90: Attenuon’s Included Lymphoma Pipeline and Competitive Fall-Out 698
Table 91: AVEO’s Included Lymphoma Pipeline and Competitive Fall-Out 699
Table 92: Bayer’s Included Lymphoma Pipeline and Competitive Fall-Out 700
Table 93: Benitec’s Included Lymphoma Pipeline and Competitive Fall-Out 701
Table 94: Biocon’s Included Lymphoma Pipeline and Competitive Fall-Out 702
Table 95: BioCryst Pharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out 703
Table 96: Biogen Idec’s Included Lymphoma Pipeline and Competitive Fall-Out 704
Table 97: Biolex’s Included Lymphoma Pipeline and Competitive Fall-Out 709
Table 98: Boehringer Ingelheim’s Included Lymphoma Pipeline and Competitive Fall-Out 711
Table 99: Borean Pharma’s Included Lymphoma Pipeline and Competitive Fall-Out 712
Table 100: Bristol-Myers Squibb’s Included Lymphoma Pipeline and Competitive Fall-Out 714
Table 101: BTG’s Included Lymphoma Pipeline and Competitive Fall-Out 721
Table 102: Celera’s Included Lymphoma Pipeline and Competitive Fall-Out 724
Table 103: Celgene’s Included Lymphoma Pipeline and Competitive Fall-Out 726
Table 104: Cell Therapeutics’ Included Lymphoma Pipeline and Competitive Fall-Out 729
Table 105: Celldex Therapeutics’ Included Lymphoma Pipeline and Competitive Fall-Out 731
Table 106: Celltrion’s Included Lymphoma Pipeline and Competitive Fall-Out 733
Table 107: Cephalon’s Included Lymphoma Pipeline and Competitive Fall-Out 735
Table 108: Cornerstone Pharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out 739
Table 109: CureTech’s Included Lymphoma Pipeline and Competitive Fall-Out 740
Table 110: Curis’ Included Lymphoma Pipeline and Competitive Fall-Out 741
Table 111: Cyclacel’s Included Lymphoma Pipeline and Competitive Fall-Out 742
Table 112: Cylene Pharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out 743
Table 113: CytImmune Sciences’ Included Lymphoma Pipeline and Competitive Fall-Out 745
Table 114: Cytokinetics’ Included Lymphoma Pipeline and Competitive Fall-Out 746
Table 115: Daiichi Sankyo’s Included Lymphoma Pipeline and Competitive Fall-Out 748
Table 116: Dainippon Sumitomo Pharma’s Included Lymphoma Pipeline and Competitive Fall-Out 750
Table 117: Dara Biosciences’ Included Lymphoma Pipeline and Competitive Fall-Out 752
Table 118: Dendreon’s Included Lymphoma Pipeline and Competitive Fall-Out 753
Table 119: Dr Reddy’s’ Included Lymphoma Pipeline and Competitive Fall-Out 754
Table 120: Dynavax Technologies’ Included Lymphoma Pipeline and Competitive Fall-Out 756
Table 121: Eisai’s Included Lymphoma Pipeline and Competitive Fall-Out 757
Table 122: Eleos’ Included Lymphoma Pipeline and Competitive Fall-Out 759
Table 123: Eli Lilly’s Included Lymphoma Pipeline and Competitive Fall-Out 760
Table 124: Emergent BioSolutions’ Included Lymphoma Pipeline and Competitive Fall-Out 764
Table 125: Enzon’s Included Lymphoma Pipeline and Competitive Fall-Out 767
Table 126: EpiCept’s Included Lymphoma Pipeline and Competitive Fall-Out 768
Table 127: Epizyme’s Included Lymphoma Pipeline and Competitive Fall-Out 769
Table 128: Exelixis’ Included Lymphoma Pipeline and Competitive Fall-Out 770
Table 129: Favrille’s Included Lymphoma Pipeline and Competitive Fall-Out 774
Table 130: Forma Therapeutics’ Included Lymphoma Pipeline and Competitive Fall-Out 776
Table 131: Gemin X Biotechnologies’ Included Lymphoma Pipeline and Competitive Fall-Out 777
Table 132: Genencor’s Included Lymphoma Pipeline and Competitive Fall-Out 778
Table 133: Genentech’s Included Lymphoma Pipeline and Competitive Fall-Out 779
Table 134: Genmab’s Included Lymphoma Pipeline and Competitive Fall-Out 781
Table 135: GenPat77’s Included Lymphoma Pipeline and Competitive Fall-Out 784
Table 136: Genta’s Included Lymphoma Pipeline and Competitive Fall-Out 785
Table 137: Genzyme’s Included Lymphoma Pipeline and Competitive Fall-Out 786
Table 138: Gilead Sciences’ Included Lymphoma Pipeline and Competitive Fall-Out 788
Table 139: GlaxoSmithKline’s Included Lymphoma Pipeline and Competitive Fall-Out 790
Table 140: Hayashibara’s Included Lymphoma Pipeline and Competitive Fall-Out 796
Table 141: Heber Biotec’s Included Lymphoma Pipeline and Competitive Fall-Out 797
Table 142: HemaQuest’s Included Lymphoma Pipeline and Competitive Fall-Out 798
Table 143: Hoffmann-La Roche’s Included Lymphoma Pipeline and Competitive Fall-Out 799
Table 144: Human Genome Sciences’ Included Lymphoma Pipeline and Competitive Fall-Out 805
Table 145: Hy BioPharma’s Included Lymphoma Pipeline and Competitive Fall-Out 807
Table 146: IGF Oncology’s Included Lymphoma Pipeline and Competitive Fall-Out 808
Table 147: ImmunoGen’s Included Lymphoma Pipeline and Competitive Fall-Out 809
Table 148: Immunomedics’ Included Lymphoma Pipeline and Competitive Fall-Out 810
Table 149: Inex’s Included Lymphoma Pipeline and Competitive Fall-Out 814
Table 150: Innate Pharma’s Included Lymphoma Pipeline and Competitive Fall-Out 815
Table 151: InNexus Biotechnology’s Included Lymphoma Pipeline and Competitive Fall-Out 817
Table 152: Inovio’s Included Lymphoma Pipeline and Competitive Fall-Out 820
Table 153: Intas Biopharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out 821
Table 154: Intracel’s Included Lymphoma Pipeline and Competitive Fall-Out 822
Table 155: Italfarmaco’s Included Lymphoma Pipeline and Competitive Fall-Out 824
Table 156: Johnson & Johnson’s Included Lymphoma Pipeline and Competitive Fall-Out 825
Table 157: Kinex’s Included Lymphoma Pipeline and Competitive Fall-Out 827
Table 158: Kissei’s Included Lymphoma Pipeline and Competitive Fall-Out 828
Table 159: Kyowa Hakko Kirin’s Included Lymphoma Pipeline and Competitive Fall-Out 830
Table 160: Leo’s Included Lymphoma Pipeline and Competitive Fall-Out 833
Table 161: LG Life Sciences’ Included Lymphoma Pipeline and Competitive Fall-Out 834
Table 162: Ligand’s Included Lymphoma Pipeline and Competitive Fall-Out 836
Table 163: Lorus Therapeutics’ Included Lymphoma Pipeline and Competitive Fall-Out 838
Table 164: MacroGenics’ Included Lymphoma Pipeline and Competitive Fall-Out 840
Table 165: Meda’s Included Lymphoma Pipeline and Competitive Fall-Out 841
Table 166: MedImmune’s Included Lymphoma Pipeline and Competitive Fall-Out 843
Table 167: Merck & Co’s Included Lymphoma Pipeline and Competitive Fall-Out 844
Table 168: Merck KGaA’s Included Lymphoma Pipeline and Competitive Fall-Out 846
Table 169: MethylGene’s Included Lymphoma Pipeline and Competitive Fall-Out 848
Table 170: Micromet’s Included Lymphoma Pipeline and Competitive Fall-Out 850
Table 171: Nektar Therapeutics’ Included Lymphoma Pipeline and Competitive Fall-Out 852
Table 172: Nereus Pharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out 853
Table 173: Nerviano Medical Sciences’ Included Lymphoma Pipeline and Competitive Fall-Out 854
Table 174: NIH’s Included Lymphoma Pipeline and Competitive Fall-Out 855
Table 175: Non-industrial Source’s Included Lymphoma Pipeline and Competitive Fall-Out 856
Table 176: Novartis’ Included Lymphoma Pipeline and Competitive Fall-Out 858
Table 177: Noxxon’s Included Lymphoma Pipeline and Competitive Fall-Out 863
Table 178: Nycomed Pharma’s Included Lymphoma Pipeline and Competitive Fall-Out 864
Table 179: Onconova’s Included Lymphoma Pipeline and Competitive Fall-Out 866
Table 180: Oncothyreon’s Included Lymphoma Pipeline and Competitive Fall-Out 868
Table 181: Otsuka’s Included Lymphoma Pipeline and Competitive Fall-Out 869
Table 182: Pfizer’s Included Lymphoma Pipeline and Competitive Fall-Out 870
Table 183: Pharmacyclics’ Included Lymphoma Pipeline and Competitive Fall-Out 876
Table 184: PharmaMar’s Included Lymphoma Pipeline and Competitive Fall-Out 878
Table 185: Philogen’s Included Lymphoma Pipeline and Competitive Fall-Out 880
Table 186: Piramal’s Included Lymphoma Pipeline and Competitive Fall-Out 881
Table 187: Plexxikon’s Included Lymphoma Pipeline and Competitive Fall-Out 883
Table 188: Portola Pharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out 884
Table 189: ProNAi Therapeutics’ Included Lymphoma Pipeline and Competitive Fall-Out 886
Table 190: Reata Pharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out 887
Table 191: Regeneron’s Included Lymphoma Pipeline and Competitive Fall-Out 888
Table 192: Reliance Life Sciences’ Included Lymphoma Pipeline and Competitive Fall-Out 889
Table 193: Rigel’s Included Lymphoma Pipeline and Competitive Fall-Out 890
Table 194: Sanofi-Aventis’ Included Lymphoma Pipeline and Competitive Fall-Out 892
Table 195: Santaris Pharma’s Included Lymphoma Pipeline and Competitive Fall-Out 895
Table 196: SBIO’s Included Lymphoma Pipeline and Competitive Fall-Out 897
Table 197: Seattle Genetics’ Included Lymphoma Pipeline and Competitive Fall-Out 898
Table 198: Selvita’s Included Lymphoma Pipeline and Competitive Fall-Out 901
Table 199: Semafore Pharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out 902
Table 200: Shire’s Included Lymphoma Pipeline and Competitive Fall-Out 903
Table 201: SuperGen’s Included Lymphoma Pipeline and Competitive Fall-Out 904
Table 202: SuppreMol’s Included Lymphoma Pipeline and Competitive Fall-Out 906
Table 203: Synageva BioPharma’s Included Lymphoma Pipeline and Competitive Fall-Out 907
Table 204: Takeda’s Included Lymphoma Pipeline and Competitive Fall-Out 909
Table 205: Tapestry Pharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out 912
Table 206: Tekmira Pharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out 914
Table 207: Telik’s Included Lymphoma Pipeline and Competitive Fall-Out 915
Table 208: TetraLogic Pharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out 916
Table 209: Teva’s Included Lymphoma Pipeline and Competitive Fall-Out 917
Table 210: Titan Pharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out 919
Table 211: TopoTarget’s Included Lymphoma Pipeline and Competitive Fall-Out 920
Table 212: Transgene’s Included Lymphoma Pipeline and Competitive Fall-Out 922
Table 213: Trion Pharma’s Included Lymphoma Pipeline and Competitive Fall-Out 923
Table 214: Vaccinex’s Included Lymphoma Pipeline and Competitive Fall-Out 925
Table 215: VentiRx Pharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out 927
Table 216: Vertex Pharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out 928
Table 217: Vion Pharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out 929
Table 218: XBiotech’s Included Lymphoma Pipeline and Competitive Fall-Out 931
Table 219: Xencor’s Included Lymphoma Pipeline and Competitive Fall-Out 932
Table 220: Yakult Honsha’s Included Lymphoma Pipeline and Competitive Fall-Out 934
Table 221: Zenotech’s Included Lymphoma Pipeline and Competitive Fall-Out 935
Table 222: Zenyaku Kogyo’s Included Lymphoma Pipeline and Competitive Fall-Out 937

This report includes 152 companies plus their collaborators:
4SC
Abbott
Abiogen
Advaxis
AEgera
AEterna Zentaris
Affimed Therapeutics
Agenus
Aida Pharmaceuticals
Alfa Wassermann
Alfacell
Allos Therapeutics
Ambit Biosciences
Amgen
Apricus Biosciences
Ariad
Arno Therapeutics
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
Bayer
Benitec
Biocon
BioCryst Pharmaceuticals
Biogen Idec
Biolex
Boehringer Ingelheim
Borean Pharma
Bristol-Myers Squibb
BTG
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celltrion
Cephalon
Cornerstone Pharmaceuticals
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
CytImmune Sciences
Cytokinetics
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Dendreon
Dr Reddy’s
Dynavax Technologies
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
Enzon
EpiCept
Epizyme
Exelixis
Favrille
Forma Therapeutics
Gemin X Biotechnologies
Genencor
Genentech
Genmab
GenPat77
Genta
Genzyme
Gilead Sciences
GlaxoSmithKline
Hayashibara
Heber Biotec
HemaQuest
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
IGF Oncology
ImmunoGen
Immunomedics
Inex
Innate Pharma
InNexus Biotechnology
Inovio
Intas Biopharmaceuticals
Intracel
Italfarmaco
Johnson & Johnson
Kinex
Kissei
Kyowa Hakko Kirin
Leo
LG Life Sciences
Ligand
Lorus Therapeutics
MacroGenics
Meda
MedImmune
Merck & Co
Merck KGaA
MethylGene
Micromet
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Novartis
Noxxon
Nycomed Pharma
Onconova
Oncothyreon
Otsuka
Pfizer
Pharmacyclics
PharmaMar
Philogen
Piramal
Plexxikon
Portola Pharmaceuticals
ProNAi Therapeutics
Reata Pharmaceuticals
Regeneron
Reliance Life Sciences
Rigel
Sanofi-Aventis
Santaris Pharma
SBIO
Seattle Genetics
Selvita
Semafore Pharmaceuticals
Shire
SuperGen
SuppreMol
Synageva BioPharma
Takeda
Tapestry Pharmaceuticals
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Titan Pharmaceuticals
TopoTarget
Transgene
Trion Pharma
Vaccinex
VentiRx Pharmaceuticals
Vertex Pharmaceuticals
Vion Pharmaceuticals
XBiotech
Xencor
Yakult Honsha
Zenotech
Zenyaku Kogyo
This report includes 282 cancer drugs. From Ceased to Marketed. Some examples are:
131I-tositumomab
alemtuzumab
amrubicin hydrochloride
belinostat
bexarotene
bortezomib
brentuximab vedotin
cladribine
denileukin diftitox
elliptinium acetate
enzastaurin hydrochloride
epirubicin
everolimus
galiximab
HBP-347
ibritumomab tiuxetan
inotuzumab ozogamicin
interferon (alpha)
interferon (alpha2b)
interferon (gamma)
interferon alpha-2b
irinotecan hydrochloride
mitoxantrone
obinutuzumab
oblimersen sodium
ofatumumab
panobinostat
pixantrone
pralatrexate
razoxane
Reditux
rhIFN-alpha
rituximab
romidepsin
sobuzoxane
temsirolimus
teniposide
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market.
    To find out more about A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market
This report comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 217 companies, from Ceased to Marketed. The report extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and three subindications of lung cancer. Learn More


Large Pharma:2004 a year of Progress
BioSeeker Group analyzes the progress made by the large pharmaceutical companies top oncology drug candidates whom has reached Phase III clinical evaluation. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Lung Cancer, Melanoma and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Melanoma and by the mechanism/target/effect of Angiogenesis. Learn More


Protein Kinase Therapeutics in Oncology - Where to Commercialize?
This report is an important part of creating and implementing a market development plan for any protein kinase drug in oncology to ensure that the optimal market conditions exist by the time the product is commercialized. Learn More